Bristol-Myers Squ…
USUSDBristol-Myers Squibb Company (XETRA:BRM) — Drug Manufacturers - General. Número de bolsas en las que cotizan las acciones de la empresa: 6. En esta página: cotización y gráfico, dividendos, principales accionistas e historial del número de acciones.
Sobre la Empresa
- Sitio Web
- bms.com
- Relaciones con los Inversores
- bms.com/investors.html
- Sector
- Healthcare · Drug Manufacturers - General
- Sede Central
- PRINCETON, United States
- Consejero Delegado
- Christopher S. Boerner
- Empleados
- 32 500
- Fundada
- 1989
- Acciones en Circulación
- 2.04 mil M a 2026-07-22
- Capital Flotante
- 2.04 mil M
- Capitalización Bursátil
- 128.41 mil M USD
- Insiders
- 0.1%
- Inversores Institucionales
- 84.87%
- Industria (SIC)
- Pharmaceutical Preparations
- Forma Jurídica
- XTIQ
- ISIN
- US1101221083
- LEI
- HLYYNH7UQUORYSJQCN42
- P/E
- 13.8
- Ratio de Reparto
- 54.9%
- FCF
- 11.4 mil M USD
- Payout / FCF
- 45%
- Deuda
- 43.9 mil M USD3.1 a. de FCF
- Racha de Dividendos
- 54 a.
- Beneficios, FCF y dividendos pagados — para los 12 meses hasta 30.06.2026 (el último informe de la compañía).
Descripción
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Opdualag to treat unresectable or metastatic melanoma; and Camzyos for the treatment of symptomatic obstructive HCM. The company also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu to treat moderate-to-severe plaque psoriasis; Krazati for the treatment of KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for the reduction of risk of stroke/systemic embolism and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug for multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane to treat breast cancer. Further, the company provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC, as well as NSCLC and pancreatic cancer. It sells its products to wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics, and government agencies. The company has a strategic collaboration with Arcus Biosciences, Inc. to develop a treatment regimen that delivers tumor control in kidney cancer. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.
Bolsas y Tickers
| Bolsa | Ticker | Moneda | Precio | Tipo |
|---|---|---|---|---|
| US USA Stocks | BMY principal | USD | 57.58 -2.60% | acciones ordinarias |
| LSE London Stock Exchange | 0R1F IOB | GBP | — | acciones ordinarias |
| MI Borsa Italiana (Milan) | 1BMY secundaria | EUR | 53.13 +0.28% | acciones ordinarias |
| MX Mexican Stock Exchange | BMY secundaria | MXN | 1 047 -3.81% | acciones ordinarias |
| VI Vienna Stock Exchange | BMYS secundaria | EUR | 52.98 +0.34% | acciones ordinarias |
| XETRA Xetra | BRM secundaria | EUR | 53.04 +0.89% | acciones ordinarias |
Dividendos
Bristol-Myers Squibb Company (BMYS) paga dividendos trimestralmente. Por año (12 meses hasta e incluyendo el último pago anunciado): 0.562 EUR por acción (pagos: 1). Eso representa aproximadamente el 1.06% del precio actual de la acción. Según el historial de pagos, se espera la próxima fecha ex-dividendo alrededor de 01.01.2027. Historial de dividendos ininterrumpido: 54 años.
| Fecha Ex | Pago | Importe | % | Tipo | Ticker |
|---|---|---|---|---|---|
| 2026-10-02 | — | 0.5620 EUR | 1.0/4.0 % | — | VI:BMYS |
| 2026-07-02 | — | 0.5540 EUR | 1.1/4.4 % | trimestral | XETRA:BRM |
| 2026-04-02 | — | 0.5540 EUR | 1.0/4.2 % | trimestral | XETRA:BRM |
| 2026-01-02 | — | 0.5540 EUR | 1.2/4.8 % | trimestral | XETRA:BRM |
| 2025-10-03 | — | 0.5452 EUR | 1.4/5.5 % | trimestral | XETRA:BRM |
| 2025-07-03 | — | 0.5452 EUR | 1.3/5.3 % | trimestral | XETRA:BRM |
| 2025-04-04 | — | 0.5452 EUR | 1.0/4.0 % | trimestral | XETRA:BRM |
| 2025-01-03 | — | 0.5452 EUR | 1.0/3.8 % | trimestral | XETRA:BRM |
| 2024-10-04 | — | 0.5276 EUR | 1.1/4.3 % | trimestral | XETRA:BRM |
| 2024-07-05 | — | 0.5276 EUR | 1.4/5.6 % | trimestral | XETRA:BRM |
| 2024-04-04 | — | 0.5276 EUR | 1.1/4.3 % | trimestral | XETRA:BRM |
| 2024-01-04 | — | 0.5276 EUR | 1.1/4.2 % | trimestral | XETRA:BRM |
| 2023-10-05 | — | 0.5013 EUR | 0.9/3.7 % | trimestral | XETRA:BRM |
| 2023-07-06 | — | 0.5013 EUR | 0.8/3.3 % | trimestral | XETRA:BRM |
| 2023-04-06 | — | 0.5013 EUR | 0.8/3.0 % | trimestral | XETRA:BRM |
| 2023-01-05 | — | 0.5013 EUR | 0.7/2.8 % | trimestral | XETRA:BRM |
| 2022-10-06 | — | 0.4749 EUR | 0.7/2.6 % | trimestral | XETRA:BRM |
| 2022-06-30 | — | 0.4749 EUR | 0.6/1.9 % | trimestral | XETRA:BRM |
| 2022-03-31 | — | 0.4749 EUR | 0.7/1.4 % | trimestral | XETRA:BRM |
| 2022-01-06 | — | 0.4749 EUR | 0.9/0.9 % | trimestral | XETRA:BRM |
Noticias de Esta Semana
Comunicados de prensa desde la página web para inversores de la empresa, actualizados diariamente. Los enlaces conducen a la página web de la empresa. Los titulares están en el idioma original, como en la página web de la empresa.
Principales Accionistas
| Titular | Participación | Acciones | Fecha del Informe |
|---|---|---|---|
| Blackrock Inc. | 8.83% | 180.38 M | 2026-06-30 |
| Vanguard Capital Managem… | 6.53% | 133.34 M | 2026-06-30 |
| State Street Corporation | 5.01% | 102.41 M | 2026-06-30 |
| JPMORGAN CHASE & CO | 3.51% | 71.71 M | 2026-06-30 |
| Charles Schwab Investmen… | 3.31% | 67.6 M | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 3.17% | 64.83 M | 2026-06-30 |
| Geode Capital Management… | 2.76% | 56.44 M | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 2.59% | 52.92 M | 2026-06-30 |
| SCHWAB STRATEGIC TRUST-S… | 2.38% | 48.64 M | 2026-05-31 |
| Vanguard Portfolio Manag… | 2.29% | 46.87 M | 2026-06-30 |
| NORGES BANK | 1.8% | 36.87 M | 2026-06-30 |
| Bank of America Corporat… | 1.67% | 34.05 M | 2026-06-30 |
| Price (T.Rowe) Associate… | 1.55% | 31.71 M | 2026-06-30 |
| iShares Trust-iShares Co… | 1.35% | 27.55 M | 2026-08-31 |
| Fidelity Concord Street… | 1.29% | 26.41 M | 2026-07-31 |
| SPDR S&P 500 ETF TRUST-S… | 1.22% | 24.96 M | 2026-08-31 |
| VANGUARD INDEX FUNDS-Van… | 0.95% | 19.44 M | 2026-06-30 |
| SELECT SECTOR SPDR TRT-S… | 0.72% | 14.68 M | 2026-08-31 |
| VANGUARD CHESTER FUNDS-V… | 0.7% | 14.29 M | 2026-06-30 |
| VANGUARD INSTITUTIONAL I… | 0.54% | 11.09 M | 2026-06-30 |
| LEUNG SANDRA (General Co… | ≈0.02% | 465 374 | 2025-03-10 |
| ELKINS DAVID VINCENT (Ch… | ≈0.01% | 159 542 | 2026-04-01 |
| BOERNER CHRISTOPHER S (C… | ≈0.01% | 146 890 | 2026-03-10 |
| HIRAWAT SAMIT (Officer) | ≈0% | 83 513 | 2025-04-25 |
| HALLER JULIA A (Director… | ≈0% | 34 079 | 2026-06-15 |
| MEYERS GREGORY SCOTT (Ch… | ≈0% | 30 361 | 2026-03-10 |
| LENKOWSKY ADAM (Officer) | ≈0% | 28 677 | 2026-05-01 |
| SHANAHAN KARIN (Officer) | ≈0% | 27 345 | 2026-04-01 |
| PLENGE ROBERT M (Officer… | ≈0% | 24 754 | 2026-03-10 |
| MASSACESI CRISTIAN (Offi… | ≈0% | 18 748 | 2026-09-09 |
